Cogent Biosciences Prepares Up to Three FDA Filings for Bezuclastinib Following Pivotal Wins
Cogent Biosciences is preparing parallel FDA submissions for bezuclastinib across three indications following positive pivotal trial results, with potential launches beginning in late 2026 and full commercialization expected by early 2027.